Communicating clinical trial results to non-scientific staff means translating complex data into clear, meaningful narratives without sacrificing accuracy. The most effective approach combines plain language, purposeful visual formats, and audience-specific framing — so that findings land with the weight they deserve, regardless of the reader’s scientific background. The questions below address the most common challenges teams face when bridging this communication gap internally.
Why do non-scientific staff struggle to understand clinical trial results?
The short answer: most trial data is designed for scientific peers, not business colleagues. It arrives in formats built around statistical conventions, regulatory requirements, and medical terminology that assume a level of training most internal audiences simply do not have. The gap is not one of intelligence — it is one of context.
Several specific barriers compound the problem. P-values, confidence intervals, hazard ratios, and relative risk reductions are meaningful to a statistician or clinician but opaque to a marketing manager, HR director, or sales coordinator encountering them for the first time. Beyond terminology, the sheer volume of information in a clinical study report can overwhelm anyone without a clear signal of what matters and why.
There is also a framing problem. Scientific writing is deliberately cautious — hedged with qualifications that are necessary for regulatory and peer review purposes but can read as evasive or inconclusive to a non-scientist looking for a clear takeaway. When the answer to “did it work?” is buried in a table of secondary endpoints, internal audiences disengage quickly. Effective internal communication requires someone to make deliberate choices about what to foreground, what to contextualise, and what to leave for a technical appendix.
What language should you use when presenting clinical data to non-scientists?
Use concrete, outcome-focused language that connects trial results to real-world consequences. Replace statistical constructs with plain descriptions of what happened to patients. Instead of “a statistically significant reduction in the primary endpoint,” say “patients experienced fewer relapses over 12 months.” Precision matters, but so does accessibility — and for internal audiences, accessibility usually needs to come first.
Anchor numbers in familiar references rather than presenting them in isolation. “The treatment reduced the risk of hospitalisation by roughly a quarter” is more intuitive than the same finding expressed as a 24.3% relative risk reduction. Where technical terms are unavoidable, define them briefly in parentheses the first time they appear rather than assuming shared vocabulary.
Tone matters too. Scientific writing is neutral by design, but internal communication benefits from a degree of editorial confidence. If the data support a positive conclusion, say so clearly. If the results are mixed or require qualification, explain the nuance honestly rather than obscuring it behind jargon. Non-scientific colleagues are capable of handling complexity when it is explained well — what they cannot navigate is complexity that is never unpacked.
What formats work best for communicating trial results internally?
The most effective formats are visual summaries, layered briefing documents, and short narrative overviews tailored to a specific audience. A single data-dense slide deck rarely serves everyone well. A tiered approach gives different internal teams what they actually need, at the level of detail they can use.
Visual formats are particularly powerful for non-scientific audiences. Infographics that translate key endpoints into patient-centred outcomes, simple before-and-after comparisons, and clearly labelled charts with plain-English annotations all reduce cognitive load significantly. The goal is not to make the data look impressive — it is to make it genuinely readable.
For teams that need more depth, a structured one-pager or executive summary can bridge the gap between a full clinical study report and a visual snapshot. Lead with the headline finding, explain why it matters in business or patient terms, then provide supporting detail in descending order of importance. For cross-functional communication across departments with different priorities, two or three versions of the same core briefing — each framed around the questions that matter most to that audience — will consistently outperform a single catch-all document.
How do you explain statistical significance without confusing non-scientists?
Focus on what the finding means in practice rather than how it was calculated. Statistical significance tells you that a result is unlikely to be due to chance alone — but it says nothing about whether the effect is large enough to matter clinically or commercially. Separating those two ideas is the most important clarification you can make.
A useful framing is to describe significance as a confidence threshold: “The results were strong enough that scientists are confident the effect is real, not a coincidence.” This preserves the meaning without requiring the audience to understand p-values or null hypotheses. If the context demands more precision, you can add that the conventional threshold is a probability of less than one in twenty of the result occurring by chance — but this level of detail is rarely necessary for internal briefings.
It is equally important to address what statistical significance does not mean. A result can be statistically significant but clinically modest, or it can show a meaningful effect in a small trial that needs further validation. Non-scientific colleagues often assume “significant” means “important” in the everyday sense of the word. Correcting this assumption early — and doing so without condescension — builds the kind of scientific literacy that makes future communications easier for everyone involved.
Should clinical trial results be communicated differently to different internal teams?
Yes. Each function has distinct priorities, questions, and thresholds for detail. A medical affairs team needs scientific rigour and regulatory context. A commercial or marketing team needs to understand what the data means for positioning and messaging. A patient engagement or communications team needs to understand the human story the data tells.
Tailoring does not mean changing the underlying facts — it means choosing which aspects of the data to foreground and which framing to use. For a regulatory or market access audience, leading with the primary endpoint and its confidence interval is appropriate. For a brand team, leading with the patient population and observed quality-of-life outcomes is more useful. For a leadership team seeking a board-level summary, the headline finding and its competitive context are what matter most.
Audience segmentation is a core principle of effective medical communications, and it applies just as strongly inside an organisation as it does in external-facing materials. Using a single version of trial results for all internal audiences risks serving none of them particularly well. The investment required to produce two or three tailored versions is modest compared to the cost of internal misalignment on what a trial actually demonstrated.
What are the most common mistakes when briefing non-scientific staff on trial data?
The most common mistakes are leading with methodology rather than meaning, presenting data without context, and assuming that showing the numbers is the same as communicating them. Each produces the same outcome: an audience that walks away uncertain about what the trial demonstrated or why it matters to them.
Leading with methodology is a natural instinct for scientific communicators but a significant barrier for non-scientific audiences. Explaining how the trial was designed and powered before saying what it found inverts the priority order. Most internal audiences need the headline finding first, with methodology available as supporting detail for those who want it.
Presenting data without context is a subtler but equally damaging mistake. A 15% improvement in a primary endpoint means very little to a non-scientist without knowing what the comparator was, what the standard of care looks like, or what typically counts as a meaningful clinical difference in that disease area. Context is what transforms a number into a finding.
Many briefings also underestimate the importance of visual clarity. Tables of raw data, poorly labelled charts, and slides crowded with footnotes all signal that the communication was designed for a different audience. Stripping a briefing document back to its essential message and presenting it in clean, well-structured formats is not dumbing down — it is a professional discipline that reflects genuine respect for the audience’s time and attention.
How Wizzard helps with communicating clinical trial results internally
We work at the intersection of scientific rigour and creative communication, helping pharmaceutical and healthcare organisations bridge the gap between clinical data and the people who need to act on it. That means taking scientifically complex material and making it land with clarity and impact across diverse internal audiences — without losing accuracy in the process.
- Audience-specific briefing documents and executive summaries tailored to commercial, medical affairs, market access, and leadership teams
- Plain-language narrative development that preserves scientific accuracy while improving readability
- Visual communication design, including infographics and data visualisation, that makes trial findings accessible without oversimplifying
- Internal workshops and training materials that build scientific literacy across non-clinical functions
- Strategic framing to ensure internal communications align with external messaging and regulatory positioning
If your organisation is preparing to communicate clinical trial results across departments and needs support making the science genuinely understood, get in touch with Wizzard to discuss how we can help.